A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer.

CONCLUSIONS: Targeted inhibition of the coagulation cascade was achieved by administering PCI-27483. PCI-27483-gemcitabine was well tolerated, but superiority to single agent gemcitabine was not demonstrated.
PMID: 30844808 [PubMed - as supplied by publisher]

Source: Oncology - March 6, 2019 Category: Cancer & Oncology Authors: Ramanathan RK, Thomas GW, Khorana AA, Shah S, Zhou C, Wong S, Cole G, James D, Gabrail NY Tags: Oncology Source Type: research